← Back to Clinical Trials
Recruiting NCT04442789

NCT04442789 Sequelae of Sars-CoV-2 Infections

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04442789
Status Recruiting
Phase
Sponsor University of Giessen
Condition Lung Diseases
Study Type OBSERVATIONAL
Enrollment 120 participants
Start Date 2020-05-20
Primary Completion 2025-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 120 participants in total. It began in 2020-05-20 with a primary completion date of 2025-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

By the end of 2019 a new coronavirus, named SARS-CoV-2, was discovered in patients with pneumonia in Wuhan, China. In the following weeks and months the virus spread globally, having a tremendous impact on global health and economy. To date, no vaccine or therapy is available. Severe courses of the infection not only affect the lungs, but also other organs like the heart, kidney, or liver. The lack of preexisting immunity might at least partially explain the affection of extra pulmonary organs not yet seen in infections due to other respiratory viruses. In this observational investigation the study group will follow up on patients that have been hospitalized due to a SARS-CoV-2 infection, and monitor sequelae in various organs, with an emphasis on the pulmo-cardiovascular system. Our that in some patients, organ damage will persist and require long-term medical care.

Eligibility Criteria

Inclusion Criteria: * hospitalization due to Sars-CoV-2 infection Exclusion Criteria: * under 18 years of age

Contact & Investigator

Central Contact

Ulrich Matt, MD, PhD

✉ ulrich.matt@innere.med.uni-giessen.de

📞 0049-(0)641-985-58773

Frequently Asked Questions

Who can join the NCT04442789 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04442789 currently recruiting?

Yes, NCT04442789 is actively recruiting participants. Contact the research team at ulrich.matt@innere.med.uni-giessen.de for enrollment information.

Where is the NCT04442789 trial being conducted?

This trial is being conducted at Giessen, Germany.

Who is sponsoring the NCT04442789 clinical trial?

NCT04442789 is sponsored by University of Giessen. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology